Copyright
©2010 Baishideng. All rights reserved.
World J Stem Cells. Apr 26, 2010; 2(2): 13-17
Published online Apr 26, 2010. doi: 10.4252/wjsc.v2.i2.13
Published online Apr 26, 2010. doi: 10.4252/wjsc.v2.i2.13
Mesenchymal stem cells: From bench to bedside
Teng Ma, Department of Chemical and Biomedical Engineering, Florida State University, 2525 Pottsdamer Street, Tallahassee, FL 32310, United States
Author contributions: Ma T contributed solely to this editorial.
Correspondence to: Teng Ma, PhD, Associate Professor, Department of Chemical and Biomedical Engineering, Florida State University, 2525 Pottsdamer Street, Tallahassee, FL 32310, United States. teng@eng.fsu.edu
Telephone: +1-850-4106558 Fax: +1-850-4106150
Received: January 25, 2010
Revised: March 10, 2010
Accepted: March 17, 2010
Published online: April 26, 2010
Revised: March 10, 2010
Accepted: March 17, 2010
Published online: April 26, 2010
Abstract
Human mesenchymal stem cells (hMSCs) have tremendous promise for use in a variety of clinical applications. The ability of these cells to self-renew and differentiate into multiple tissues makes them an attractive cell source for a new generation of cell-based regenerative therapies. Encouraging results from clinical trials have also generated growing enthusiasm regarding MSC therapy and related treatment, but gaps remain in understanding MSC tissue repair mechanisms and in clinical strategies for efficient cell delivery and consistent therapeutic outcomes. For these reasons, discoveries from basic research and their implementation in clinical trials are essential to advance MSC therapy from the laboratory bench to the patient’s bedside.